Invivo Anti-Human PD-L1 (B7-H1) Recombinant mAb

PD-L1 is a ~33 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily that functions as the key ligand for the inhibitory receptor PD-1 on T cells; upon IFN-γ–driven up-regulation on dendritic cells, macrophages, normal epithelia and many tumors, its engagement of PD-1 delivers a “stop” signal that blocks T-cell receptor signaling, suppressing proliferation, cytokine production and cytotoxic activity, thereby maintaining peripheral tolerance and preventing autoimmunity, but is exploited by cancers to evade immune destruction, making the PD-1/PD-L1 axis a central target for modern checkpoint-inhibitor immunotherapies.